Date: 2016-09-21
Type of information: Development agreement
Compound:
Company: Bayer Healthcare (Germany) Evotec (Germany)
Therapeutic area: Kidney diseases - Renal diseases
Type agreement: development
Action mechanism:
Disease: kidney diseases such as chronic kidney disease in diabetes patients
Details: * On September 21, 2016, Evotec and Bayer have entered into a five-year, multi-target research partnership. The goal is the development of multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options for these severe conditions. The partners will share responsibilities during pre-clinical development of potential clinical candidates.
Under the terms of the agreement, Bayer will receive exclusive access to selected candidates as well as to Evotec’s CureNephron target pipeline. Bayer will be responsible for any subsequent clinical development and commercialisation.
In 2012, Bayer and Evotec already entered into a five-year partnership in the therapeutic area of endometriosis. Currently in its fourth year, this alliance has delivered four pre-clinical candidates and one first-in-class clinical programme has been initiated. CureNephron is a joint initiative in the field of kidney disease between Evotec and Harvard University, Brigham and Women’s Hospital and University of Southern California. The initiative has been initiated in 2012 and underlines the value of Evotec’s academic bridge model, which translates excellent science from academic institutions to Pharma. Within CureNephron, systematic and unbiased approaches are pursued towards the identification of kidney disease relevant mechanisms with particular interest in mechanisms with disease-modifying potential. CureNephron is designed to deliver and exploit novel therapeutic targets as well as biomarkers that allow more accurate diagnosis, monitoring and treatment of chronic and acute kidney disease.
Financial terms: Evotec will receive a minimum of € 14 million over the contract period including research payments and an undisclosed licence fee. In addition, Evotec is eligible to receive pre-clinical, clinical and sales milestones of potentially over € 300 million as well as tiered royalties of up to low double-digit percentage of net sales.
Latest news:
